Pacific released a research report on April 16 stating that it gave Biotai (688177.SH) a purchase rating. The main reasons for the rating include: 1) self-exemption and anti-tumor drugs drive rapid revenue growth; 2) multiple biosimilar drugs go overseas to contribute to revenue flexibility; 3) the smooth progress of the innovative drug pipeline. (Mainichi Keizai Shimbun)
太平洋4月16日发布研报称，给予百奥泰（688177.SH）买入评级。评级理由主要包括：1）自免和抗肿瘤药物带动收入快速增长；2）多款生物类似药出海贡献收入弹性；3）创新药管线顺利推进。（每日经济新闻）
Pacific released a research report on April 16 stating that it gave Biotai (688177.SH) a purchase rating. The main reasons for the rating include: 1) self-exemption and anti-tumor drugs drive rapid revenue growth; 2) multiple biosimilar drugs go overseas
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated